These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

279 related items for PubMed ID: 17703139

  • 1. Pharmacokinetic and pharmacodynamic interaction between tolvaptan, a non-peptide AVP antagonist, and furosemide or hydrochlorothiazide.
    Shoaf SE, Bramer SL, Bricmont P, Zimmer CA.
    J Cardiovasc Pharmacol; 2007 Aug; 50(2):213-22. PubMed ID: 17703139
    [Abstract] [Full Text] [Related]

  • 2. Effects of V2-receptor antagonist tolvaptan and the loop diuretic furosemide in rats with heart failure.
    Veeraveedu PT, Watanabe K, Ma M, Palaniyandi SS, Yamaguchi K, Kodama M, Aizawa Y.
    Biochem Pharmacol; 2008 Mar 15; 75(6):1322-30. PubMed ID: 18179782
    [Abstract] [Full Text] [Related]

  • 3. Potent aquaretic agent. A novel nonpeptide selective vasopressin 2 antagonist (OPC-31260) in men.
    Ohnishi A, Orita Y, Okahara R, Fujihara H, Inoue T, Yamamura Y, Yabuuchi Y, Tanaka T.
    J Clin Invest; 1993 Dec 15; 92(6):2653-9. PubMed ID: 8254021
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Effects of tolvaptan on systemic and renal hemodynamic function in dogs with congestive heart failure.
    Onogawa T, Sakamoto Y, Nakamura S, Nakayama S, Fujiki H, Yamamura Y.
    Cardiovasc Drugs Ther; 2011 Dec 15; 25 Suppl 1():S67-76. PubMed ID: 22120095
    [Abstract] [Full Text] [Related]

  • 9. Effects of hydrochlorothiazide on the pharmacokinetics, pharmacodynamics, and tolerability of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants.
    Devineni D, Vaccaro N, Polidori D, Rusch S, Wajs E.
    Clin Ther; 2014 May 15; 36(5):698-710. PubMed ID: 24726680
    [Abstract] [Full Text] [Related]

  • 10. Oral V2 receptor antagonist (RWJ-351647) in patients with cirrhosis and ascites: a randomized, double-blind, placebo-controlled, single ascending dose study.
    Thuluvath PJ, Maheshwari A, Wong F, Yoo HW, Schrier RW, Parikh C, Steare S, Korula J.
    Aliment Pharmacol Ther; 2006 Sep 15; 24(6):973-82. PubMed ID: 16948809
    [Abstract] [Full Text] [Related]

  • 11. Effects of nonpeptide vasopressin V2 antagonist tolvaptan in rats with heart failure.
    Veeraveedu PT, Watanabe K, Ma M, Palaniyandi SS, Yamaguchi K, Suzuki K, Kodama M, Aizawa Y.
    Biochem Pharmacol; 2007 Nov 15; 74(10):1466-75. PubMed ID: 17720144
    [Abstract] [Full Text] [Related]

  • 12. Tolvaptan, an orally active vasopressin V(2)-receptor antagonist - pharmacology and clinical trials.
    Miyazaki T, Fujiki H, Yamamura Y, Nakamura S, Mori T.
    Cardiovasc Drug Rev; 2007 Nov 15; 25(1):1-13. PubMed ID: 17445084
    [Abstract] [Full Text] [Related]

  • 13. Pharmacokinetic profiles of hydrochlorothiazide alone and in combination with benazepril or valsartan in healthy Chinese volunteers: evaluation of the potential interaction.
    Jiang J, Tian L, Huang Y, Xie S, Xu L, Liu H, Li Y.
    Int J Clin Pharmacol Ther; 2011 Dec 15; 49(12):756-64. PubMed ID: 22122818
    [Abstract] [Full Text] [Related]

  • 14. Assessment of the drug-drug interactions between fimasartan and hydrochlorothiazide in healthy volunteers.
    Jeon H, Lim KS, Shin KH, Kim J, Yoon SH, Cho JY, Shin SG, Jang IJ, Yu KS.
    J Cardiovasc Pharmacol; 2012 Jan 15; 59(1):84-91. PubMed ID: 21934629
    [Abstract] [Full Text] [Related]

  • 15. Pharmacokinetics, pharmacodynamics and safety of tolvaptan, a novel, oral, selective nonpeptide AVP V2-receptor antagonist: results of single- and multiple-dose studies in healthy Japanese male volunteers.
    Kim SR, Hasunuma T, Sato O, Okada T, Kondo M, Azuma J.
    Cardiovasc Drugs Ther; 2011 Dec 15; 25 Suppl 1():S5-17. PubMed ID: 22120090
    [Abstract] [Full Text] [Related]

  • 16. Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure.
    Costello-Boerrigter LC, Smith WB, Boerrigter G, Ouyang J, Zimmer CA, Orlandi C, Burnett JC.
    Am J Physiol Renal Physiol; 2006 Feb 15; 290(2):F273-8. PubMed ID: 16189291
    [Abstract] [Full Text] [Related]

  • 17. Furosemide pharmacokinetics and pharmacodynamics following gastroretentive dosage form administration to healthy volunteers.
    Klausner EA, Lavy E, Stepensky D, Cserepes E, Barta M, Friedman M, Hoffman A.
    J Clin Pharmacol; 2003 Jul 15; 43(7):711-20. PubMed ID: 12856384
    [Abstract] [Full Text] [Related]

  • 18. Gender effect on diuretic response to hydrochlorothiazide and furosemide.
    Franson KL, Kuk JM, Lam NP, Lau AH.
    Int J Clin Pharmacol Ther; 1996 Mar 15; 34(3):101-5. PubMed ID: 8705087
    [Abstract] [Full Text] [Related]

  • 19. In vitro P-glycoprotein interactions and steady-state pharmacokinetic interactions between tolvaptan and digoxin in healthy subjects.
    Shoaf SE, Ohzone Y, Ninomiya S, Furukawa M, Bricmont P, Kashiyama E, Mallikaarjun S.
    J Clin Pharmacol; 2011 May 15; 51(5):761-9. PubMed ID: 20679500
    [Abstract] [Full Text] [Related]

  • 20. Renal effects of conivaptan, furosemide, and the combination in patients with chronic heart failure.
    Goldsmith SR, Gilbertson DT, Mackedanz SA, Swan SK.
    J Card Fail; 2011 Dec 15; 17(12):982-9. PubMed ID: 22123359
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.